DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2004/0116357 A1 Fushimi Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

US 2004O116357A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0116357 A1 Fushimi et al. (43) Pub. Date: Jun. 17, 2004 (54) GLUCOPYRANOSYLOXYPYRAZOLE DERVATIVES AND MEDICINAL USE THEREOF (I) (76) Inventors: Nobuhiko Fushimi, Matsumoto-shi (JP); Hideki Fujikura, Matsumoto-shi (JP); Toshihiro Nishimura, Minamiazumi-gun (JP); Kenji Katsuno, Kamiina-gun (JP); Masayuki Isaji, Shiojiri-shi (JP) Correspondence Address: SUGHRUE MION, PLLC 2100 PENNSYLVANIAAVENUE, N.W. SUTE 800 WASHINGTON, DC 20037 (US) (21) Appl. No.: 10/469,140 (22) PCT Filed: Feb. 26, 2002 (86) PCT No.: PCT/JP02/01708 wherein R', R and R represent a hydrogen atom or a (30) Foreign Application Priority Data halogen atom; R" represents a lower alkyl group or a halo(lower alkyl) group; and R represents a hydrogen atom, Feb. 27, 2001 (JP)...................................... 2001-053085 a lower alkyl group, a lower alkoxy group, a lower alkylthio group, etc., a pharmaceutically acceptable Salt thereof or a Publication Classification prodrug thereof., which exert an excellent inhibitory activity (51) Int. Cl. ................................................ A61K 31/7056 in human SGLT2, and therefore are useful as drugs for the (52) U.S. Cl. ............................................. 514/23: 536/17.4 prevention or treatment of a disease associated with hyper glycemia Such as diabetes, diabetic complications or obesity, (57) ABSTRACT pharmaceutically acceptable Salts thereof or prodrugs The present invention provides glucopyranosyloxypyrazole thereof, production intermediates thereof and pharmaceuti derivatives represented by the general formula: cal uses thereof. US 2004/0116357 A1 Jun. 17, 2004 GLUCOPYRANOSYLOXYPYRAZOLE 0005. In recent years, development of new type antidia DERVATIVES AND MEDICINAL USE THEREOF betic agents has been progressing, which promote urinary glucose excretion and lower blood glucose level by prevent TECHNICAL FIELD ing excess glucose reabsorption at the kidney (J. Clin. 0001. The present invention relates to glucopyopyrano Invest., Vol. 79, pp. 1510-1515 (1987)). In addition, it is Syloxypyrazole derivatives, pharmaceutically acceptable reported that SGLT2 (Na"/glucose cotransporter 2) is present in the S1 Segment of the kidney's proximal tubule Salts thereof or prodrugs thereof which are useful as medi and participates mainly in reabsorption of glucose filtrated caments, production intermediates thereof and pharmaceu through glomerular (J. Clin. Invest., Vol.93, pp.397-404 tical uses thereof. (1994)). Accordingly, inhibiting a human SGLT2 activity 0002 More particularly, the present invention relates to prevents reabsorption of excess glucose at the kidney, Sub glucopyranosyloxypyrazole derivatives which have an Sequently promotes excreting excess glucose though the inhibitory activity in human SGLT2, represented by the urine, and normalizes blood glucose level. Therefore, fast general formula: development of antidiabetic agents, which have a potent (I) inhibitory activity in human SGLT2 and have a new mecha nism, has been desired. In addition, Since Such agents promote the excretion of excess glucose though the urine and consequently the glucose accumulation in the body is decreased, they are also expected to have a preventing or alleviating effect on obesity and a urinating effect. Further more, the agents are considered to be useful for various related diseases which occur accompanying the progreSS of diabetes or obesity due to hyperglycemia. 0006 AS compounds having pyrazole moiety, it is described that WAY-123783 increased an amount of excreted glucose in normal mice. However, its effects in human are not described at all (J. Med. Chem., Vol.39, pp. 3920-3928 (1996)). DISCLOSURE OF THE INVENTION 0003 wherein R, R and R may be the same or different 0007 The present inventors have studied earnestly to find and each represents a hydrogen atom or a halogen atom; R' compounds having an inhibitory activity in human SGLT2. represents a lower alkyl group or a halo (lower alkyl) group; AS a result, it was found that compounds represented by the and R represents a hydrogen atom, a lower alkyl group, a above general formula (I) show an excellent inhibitory lower alkoxy group, a lower alkylthio group, a halo(lower activity in human SGLT2, thereby forming the basis of the alkyl) group, a halogen atom, a lower alkenyl group, a cyclic present invention. lower alkyl group, a cyclic lower alkoxy group, a cyclic 0008. The present invention is to provide the following lower alkylidenemethyl group, a 5- or 6-membered aromatic glucopyranosyloxypyrazole derivatives, pharmaceutically heterocyclic group which contains 1-4 the same or different hetero atoms Selected from an oxygen atom, a Sulfur atom acceptable Salts thereof and prodrugs thereof which exert an and a nitrogen atom in the ring, a phenyl group which may inhibitory activity in human SGLT2 and show an excellent have 1-3 the same or different groups Selected from a hypoglycemic effect by excreting excess glucose in the urine halogen atom and a hydroxy group, or a group represented through preventing the reabsorption of glucose at the kidney, by the general formula: HO-A- wherein A represents a production intermediates thereof and pharmaceutical uses lower alkylene group, pharmaceutically acceptable Salts thereof. thereof or prodrugs thereof, which are useful as agents for 0009. This is, the present invention relates to a glucopy the prevention or treatment of a disease Such as diabetes, ranosyloxypyrazole derivative represented by the general diabetic complications or obesity, production intermediates formula: thereof and pharmaceutical uses thereof. (I) BACKGROUND ART R2 0004 Diabetes is one of lifestyle-related diseases with the background of change of eating habit and lack of Aly R' exercise. Hence, diet and exercise therapies are performed in X R4 patients with diabetes. Furthermore, when its sufficient R5 control and continuous performance are difficult, drug treat ment is simultaneously performed. Now, biguanides, Sulfo nylureas and insulin Sensitivity enhancers have been employed as antidiabetic agents. However, biguanides and Sulfonylureas show occasionally adverse effects Such as lactic acidosis and hypoglycemia, respectively. In a case of using insulin Sensitivity enhancers, adverse effects Such as edema are occasionally observed, and it is also concerned for advancing obesity. Therefore, in order to Solve these problems, it has been desired to develop antidiabetic agents having a new mechanism. US 2004/0116357 A1 Jun. 17, 2004 0010 wherein R', RandR may be the same or different thyroid hormone receptor agonist, a cholesterol absorption and each represents a hydrogen atom or a halogen atom; R' inhibitor, a lipase inhibitor, a microSomal triglyceride trans represents a lower alkyl group or a halo (lower alkyl) group; fer protein inhibitor, a lipoxygenase inhibitor, a carnitine and R represents a hydrogen atom, a lower alkyl group, a palmitoyl-transferase inhibitor, a Squalene Synthase inhibi lower alkoxy group, a lower alkylthio group, a halo (lower tor, a low-density lipoprotein receptor enhancer, a nicotinic alkyl) group, a halogen atom, a lower alkenyl group, a cyclic acid derivative, a bile acid Sequestrant, a Sodium/bile acid lower alkyl group, a cyclic lower alkoxy group, a cyclic cotransporter inhibitor, a cholesterol ester transfer protein lower alkylidenemethyl group, a 5- or 6-membered aromatic inhibitor, an appetite SuppreSSant, an angiotensin-converting heterocyclic group which contains 1-4 the same or different enzyme inhibitor, a neutral endopeptidase inhibitor, an hetero atoms Selected from an oxygen atom, a Sulfur atom angiotensin II receptor antagonist, an endothelin-converting and a nitrogen atom in the ring, a phenyl group which may enzyme inhibitor, an endothelin receptor antagonist, a have 1-3 the same or different groups Selected from a diuretic agent, a calcium antagonist, a vasodilating antihy halogen atom and a hydroxy group, or a group represented pertensive agent, a Sympathetic blocking agent, a centrally by the general formula: HO-A- wherein A represents a acting antihypertensive agent, an 82-adrenoceptor agonist, lower alkylene group, a pharmaceutically acceptable Salt an antiplatelets agent, a uric acid Synthesis inhibitor, a thereof or a prodrug thereof. uricoSuric agent and a urinary alkalinizer. 0.011) Also, the present invention relates to a pharmaceu 0015 The present invention relates to a method for the tical composition, a human SGLT2 inhibitor and an agent for prevention or treatment of a disease associated with hyper the prevention or treatment of a disease associated with glycemia, which comprises administering an effective hyperglycemia, which comprise as an active ingredient a amount of (A) a glucopyranosyloxypyrazole derivative rep glucopyranosyloxypyrazole derivative represented by the resented by the above general formula (I), a pharmaceuti above general formula (I), a pharmaceutically acceptable cally acceptable Salt thereof or a prodrug thereof, in com Salt thereof or a prodrug thereof. bination with (B) at least one member selected from the group consisting of an insulin Sensitivity enhancer, a glucose 0012. The present invention relates to a method for the absorption inhibitor, a biguanide, an insulin Secretion prevention or treatment of a disease associated with hyper enhancer, an insulin preparation, a glucagon receptor glycemia, which comprises administering an effective antagonist, an insulin receptor
Recommended publications
  • Endothelin System and Therapeutic Application of Endothelin Receptor

    Endothelin System and Therapeutic Application of Endothelin Receptor

    xperim ACCESS Freely available online & E en OPEN l ta a l ic P in h l a C r m f o a c l a o n l o r g u y o J Journal of ISSN: 2161-1459 Clinical & Experimental Pharmacology Research Article Endothelin System and Therapeutic Application of Endothelin Receptor Antagonists Abebe Basazn Mekuria, Zemene Demelash Kifle*, Mohammedbrhan Abdelwuhab Department of Pharmacology, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia ABSTRACT Endothelin is a 21 amino acid molecule endogenous potent vasoconstrictor peptide. Endothelin is synthesized in vascular endothelial and smooth muscle cells, as well as in neural, renal, pulmonic, and inflammatory cells. It acts through a seven transmembrane endothelin receptor A (ETA) and endothelin receptor B (ETB) receptors belongs to G protein-coupled rhodopsin-type receptor superfamily. This peptide involved in pathogenesis of cardiovascular disorder like (heart failure, arterial hypertension, myocardial infraction and atherosclerosis), renal failure, pulmonary arterial hypertension and it also involved in pathogenesis of cancer. Potentially endothelin receptor antagonist helps the treatment of the above disorder. Currently, there are a lot of trails both per-clinical and clinical on endothelin antagonist for various cardiovascular, pulmonary and cancer disorder. Some are approved by FAD for the treatment. These agents are including both selective and non-selective endothelin receptor antagonist (ETA/B). Currently, Bosentan, Ambrisentan, and Macitentan approved
  • Supplementary Information

    Supplementary Information

    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
  • I Regulations

    I Regulations

    23.2.2007 EN Official Journal of the European Union L 56/1 I (Acts adopted under the EC Treaty/Euratom Treaty whose publication is obligatory) REGULATIONS COUNCIL REGULATION (EC) No 129/2007 of 12 February 2007 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and amending Annex I to Regulation (EEC) No 2658/87 THE COUNCIL OF THE EUROPEAN UNION, (4) In the course of three such reviews it was concluded that a certain number of additional INNs and intermediates used for production and manufacture of finished pharmaceu- ticals should be granted duty-free treatment, that certain of Having regard to the Treaty establishing the European Commu- these intermediates should be transferred to the list of INNs, nity, and in particular Article 133 thereof, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs should be expanded. Having regard to the proposal from the Commission, (5) Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (1) established the Combined Nomenclature Whereas: (CN) and set out the conventional duty rates of the Common Customs Tariff. (1) In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty- (6) Regulation (EEC) No 2658/87 should therefore be amended free treatment should be granted to pharmaceutical accordingly, products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active HAS ADOPTED THIS REGULATION: ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation, specified salts, esters or hydrates of such INNs, and designated inter- Article 1 mediates used for the production and manufacture of finished products.
  • Product Data Sheet

    Product Data Sheet

    Inhibitors Product Data Sheet Sitaxsentan sodium • Agonists Cat. No.: HY-11103 CAS No.: 210421-74-2 Molecular Formula: C₁₈H₁₄ClN₂NaO₆S₂ • Molecular Weight: 476.89 Screening Libraries Target: Endothelin Receptor Pathway: GPCR/G Protein Storage: Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month SOLVENT & SOLUBILITY In Vitro DMSO : 100 mg/mL (209.69 mM; Need ultrasonic) H2O : 100 mg/mL (209.69 mM; Need ultrasonic) Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 2.0969 mL 10.4846 mL 20.9692 mL Stock Solutions 5 mM 0.4194 mL 2.0969 mL 4.1938 mL 10 mM 0.2097 mL 1.0485 mL 2.0969 mL Please refer to the solubility information to select the appropriate solvent. In Vivo 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.24 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.24 mM); Clear solution BIOLOGICAL ACTIVITY Description Sitaxsentan sodium (IPI 1040 sodium; TBC11251 sodium) is an orally active, highly selective antagonist of endothelin A receptors. In Vitro Sitaxsentan and Bosentan attenuate NTCP transport at higher concentrations, and inhibit human hepatic transporters, which provides a potential mechanism for the increased hepatotoxicity observed for these agents in the clinical setting. Only sitaxsentan decreased OATP transport (52%)[1]. Sitaxsentan and sitaxsentan combined with sildenafil completely prevent the increased expressions of endothelin-1 and of the ETB receptor.
  • Advice Concerning the Addition of Certain Pharmaceutical Products

    Advice Concerning the Addition of Certain Pharmaceutical Products

    U.S. International Trade Commission COMMISSIONERS Daniel R. Pearson, Chairman Shara L. Aranoff, Vice Chairman Jennifer A. Hillman Stephen Koplan Deanna Tanner Okun Charlotte R. Lane Robert A. Rogowsky Director of Operations Karen Laney-Cummings Director of Industries Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Advice Concerning the Addition of Certain Pharmaceutical Products and Chemical Intermediates to the Pharmaceutical Appendix to the Harmonized Tariff Schedule of the United States Investigation No. 332--476 Publication 3883 September 2006 This report was prepared principally by Office of Industries Philip Stone, Project Leader With assistance from Elizabeth R. Nesbitt Primary Reviewers David G. Michels, Office of Tariff Affairs and Trde Agreements, John Benedetto, and Nannette Christ, Office of Economics Administrative Support Brenda F. Carroll Under the direction of Dennis Rapkins, Chief Chemicals and Textiles Division ABSTRACT Under the Pharmaceutical Zero-for-Zero Initiative, which entered into force in 1995, the United States and its major trading partners eliminated tariffs on many pharmaceuticals, their derivatives, and certain chemical intermediates used to make pharmaceuticals. The U.S. list of pharmaceutical products and chemical intermediates eligible for duty-free treatment under the agreement is given in the Pharmaceutical Appendix to the Harmonized Tariff Schedule of the United States. The Pharmaceutical Appendix is periodically updated to provide duty relief for additional such products, including newly developed pharmaceuticals. This report provides advice on the third update to the agreement, in which approximately 1,300 products are proposed to receive duty-free treatment.
  • Orally Active Compound Library (96-Well)

    Orally Active Compound Library (96-Well)

    • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com Orally Active Compound Library (96-well) Product Details: Catalog Number: CS-L061 Formulation: A collection of 2244 orally active compounds supplied as pre-dissolved Solutions or Solid Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode Storage: -80°C Shipping: Blue ice Packaging: Inert gas Plate layout: CS-L061-1 1 2 3 4 5 6 7 8 9 10 11 12 a Empty Vonoprazan Mivebresib AZD0156 BAY-876 Tomivosertib PQR620 NPS-2143 R547 PAP-1 Delpazolid Empty Varenicline b Empty Varenicline (Hydrochlorid Varenicline A-205804 CI-1044 KW-8232 GSK583 Quiflapon MRK-016 Diroximel Empty e) (Tartrate) fumarate SHP099 c Empty A 922500 SHP099 (hydrochlorid Nevanimibe Pactimibe Pactimibe GNF-6231 MLi-2 KDM5-IN-1 PACMA 31 Empty e) hydrochloride (sulfate) Rilmenidine d Empty Cadazolid Treprostinil GSK3179106 Esaxerenone (hemifumarat Rilmenidine Fisogatinib BP-1-102 Avadomide Aprepitant Empty e) (phosphate) Cl-amidine AZD5153 (6- e Empty Maropitant Abscisic acid (hydrochlorid BGG463 WNK463 Ticagrelor Axitinib Hydroxy-2- CGS 15943 Pipamperone Empty e) naphthoic Setogepram Teglarinad f Empty Y-27632 GSK2193874 Lanabecestat CXD101 Ritlecitinib YL0919 PCC0208009 (sodium salt) (chloride) Futibatinib Empty TAK-659 g Empty NCB-0846 GS-444217 (hydrochlorid Navitoclax ABX464 Zibotentan Simurosertib (R)- CEP-40783 MK-8617 Empty e) Simurosertib Choline JNJ- h Empty CCT251236 (bitartrate) Sarcosine Brensocatib AS-605240 PF-06840003
  • Forschung Für Das Leben Entwicklungsprojekte Für Innovative Arzneimittel Inhalt

    Forschung Für Das Leben Entwicklungsprojekte Für Innovative Arzneimittel Inhalt

    Forschung für das Leben Entwicklungsprojekte für innovative Arzneimittel Inhalt Vorwort 1 Perspektive 2013 2 Medikamente von übermorgen 12 Wie ein neues Medikament entsteht 16 Innovationen brauchen einen soliden Rahmen 32 Schwerpunkte der vfa-Mitglieder in ihrer Forschung & Entwicklung weltweit 40 Projekte, die bis 2013 zu Zulassungen führen können 42 Der vfa ist der Verband der forschenden Pharma-Unternehmen in Deutschland. Er vertritt die Interessen von 48 weltweit führenden Herstellern und ihren über 100 Tochter- und Schwesterfi rmen in der Gesundheits-, Forschungs- und Wirtschaftspolitik. Die Mitglieder des vfa repräsentieren rund zwei Drittel des gesamten deutschen Arzneimittelmarktes und beschäftigen in Deutschland rund 90.000 Mitarbeiter. Mehr als 17.000 davon arbeiten in Forschung und Entwicklung. Vorwort alle zwei Jahre fragt der vfa – der Verband der forschenden Pharma-Unternehmen – seine Mitglieder, welche Medikamente in den folgenden vier Jahren eine Zulassung erhalten könnten. Das Ergebnis veröff entlicht er dann in einer neuen Ausgabe dieser Broschüre. Schaue ich noch einmal in die Ausgabe von 2007, stelle ich fest, wie viel die Unternehmen mittlerweile von dem eingelöst haben, was sie damals in Aussicht stellten: So haben sie für Krebskranke neue Medikamente herausgebracht, die ihre Lebenserwartung und Lebens- qualität verbessern können, etwa bei Brust- oder Nierenkrebs. Sie haben viele Patienten mit neuen resistenzbrechenden Antibiotika versorgt. Für HIV-Infi zierte stehen nun Medikamente mit zwei neuartigen Wirkprinzipien zur Verfügung, mit denen sich die Viren langfristig in Schach halten lassen. Auch gibt es mittlerweile etliche neue Präparate gegen seltene Krankheiten – etwa bestimmte Leukämien bei Kindern oder den Blutplättchen- mangel bei der Immunkrankheit „thrombozytopenische Purpura“. Zugleich erinnert die Ausgabe 2007 an einige nicht weniger ambitionierte Projekte, die zwischenzeitlich leider eingestellt werden mussten – oftmals nach mehr als zehn Jahren Forschungsarbeit.
  • Stembook 2018.Pdf

    Stembook 2018.Pdf

    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum

    A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum

    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
  • MM&M Takes a Detailed Look at Key Products in the Pipeline

    MM&M Takes a Detailed Look at Key Products in the Pipeline

    MM&M takes a detailed look at key products in the pipeline, highlighting the most promising with insights and ratings from Ptop analysts, to IPE provide an overall picture of each therapeutic’s potential value INE 2010 uerosto commodo odionul PROVOCAtiVe AGMM&M’s Pipeline 2010 drawsENTS from the best in drug development, profiling 15 agents with the highest approval probability and brightest commercial prospects. These are the prime near-term launch candidates. The report also provides updates on 202 products in a host of therapeutic areas. Marc Iskowitz reports ualitative change, rather than the quantitative kind, marks best hope to replace warfarin. Then there are the upstarts. Patients this year’s biopharmaceutical pipeline. There has been a shift with rare diseases are finally getting drugs specifically approved for Q in categories poised to yield near-term approvals. And while them. According to a new analysis by the Tufts Center for the Study not the goldmine drug marketers were hoping for, analysts expect of Drug Development, the annual rate of new product approvals the 2010 R&D seam to yield some exciting launch prospects in the worldwide for neglected diseases increased from an average of 1.8 months and years ahead. in 1975-99 to 2.6 in 2000-09. Vaccines and antiviral drugs have also Oncology, a well of innovative approvals in years past, has run seen a resurgence, with physicians talking about a possible cure for relatively dry. “In 2000-2001, we saw Avastin, Tarceva, Sutent, Nexa- hepatitis C and a number of vaccines in the pipeline for ailments var, Gleevec—drugs that revolutionized the way we think about from flu to cancer and diabetes.
  • Pro-Arrhythmic Signaling of Thyroid Hormones and Its Relevance in Subclinical Hyperthyroidism

    Pro-Arrhythmic Signaling of Thyroid Hormones and Its Relevance in Subclinical Hyperthyroidism

    International Journal of Molecular Sciences Review Pro-Arrhythmic Signaling of Thyroid Hormones and Its Relevance in Subclinical Hyperthyroidism Narcis Tribulova 1,* , Lin Hai Kurahara 2, Peter Hlivak 3, Katsuya Hirano 2 and Barbara Szeiffova Bacova 1,* 1 Centre of Experimental Medicine, Slovak Academy of Sciences, Institute for Heart Research, 84104 Bratislava, Slovakia 2 Department of Cardiovascular Physiology, Faculty of Medicine, Kagawa University, Kagawa 76 0793, Japan; [email protected] (L.H.K.); [email protected] (K.H.) 3 Department of Arrhythmias and Pacing, National Institute of Cardiovascular Diseases, Pod Krásnou Hôrkou 1, 83348 Bratislava, Slovakia; [email protected] * Correspondence: [email protected] (N.T.); [email protected] (B.S.B.); Tel.: +421-2-32295-423 (B.S.B.) Received: 13 March 2020; Accepted: 17 April 2020; Published: 19 April 2020 Abstract: A perennial task is to prevent the occurrence and/or recurrence of most frequent or life-threatening cardiac arrhythmias such as atrial fibrillation (AF) and ventricular fibrillation (VF). VF may be lethal in cases without an implantable cardioverter defibrillator or with failure of this device. Incidences of AF, even the asymptomatic ones, jeopardize the patient’s life due to its complication, notably the high risk of embolic stroke. Therefore, there has been a growing interest in subclinical AF screening and searching for novel electrophysiological and molecular markers. Considering the worldwide increase in cases of thyroid dysfunction and diseases, including thyroid carcinoma, we aimed to explore the implication of thyroid hormones in pro-arrhythmic signaling in the pathophysiological setting. The present review provides updated information about the impact of altered thyroid status on both the occurrence and recurrence of cardiac arrhythmias, predominantly AF.
  • US 2014/0057832 A1 Conrad Et Al

    US 2014/0057832 A1 Conrad Et Al

    US 20140057832A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0057832 A1 Conrad et al. (43) Pub. Date: Feb. 27, 2014 (54) USE OF RELAXN TO INCREASE ARTERAL Publication Classification COMPLIANCE (51) Int. Cl. (71) Applicants: Kirk P. Conrad, Gainesville, FL (US); A638/22 (2006.01) Sanjeev G. Shroff, Pittsburg, PA (US) (52) U.S. Cl. CPC .................................. A61 K38/2221 (2013.01) (72) Inventors: Kirk P. Conrad, Gainesville, FL (US); USPC 514/1.9; 514/12.7: 514/7.3; 514/6.9; 514/7.4 Sanjeev G. Shroff, Pittsburg, PA (US) (73) Assignee: University of Pittsburgh - Of the (57) ABSTRACT Commonwealth System of Higher Education, Pittsburgh, PA (US) The present invention provides methods for increasing arte rial compliance. The methods generally involve administer (21) Appl. No.: 14/071,705 ing to an individual in need thereof an effective amount of relaxin. The present invention further provides methods of (22) Filed: Nov. 5, 2013 increasing arterial compliance in individuals who have Type 1 or Type 2 diabetes. The present invention further provides Related U.S. Application Data methods of increasing arterial compliance in perimeno (63) Continuation of application No. 12/985,714, filed on pausal, menopausal, and post-menopausal women. The Jan. 6, 2011, now Pat. No. 8,602,998, which is a con present invention further provides methods of increasing arte tinuation of application No. 11/084,670, filed on Mar. rial compliance in individuals who have or who are at risk of 18, 2005, now Pat. No. 7,878,978. developing age-associated arterial stiffness.